Table 1.
Baseline Characteristics and Posttransplant Events of Patients by IL-18 Gene Promoter Polymorphism Haplotype
| IL18 Haplotypes | -607C/-137G Carriers (n = 419) n (%) | -607C/-137G Noncarriers (n = 79) n (%) | P |
|---|---|---|---|
| Donor age, yearsa | 43.7 (13.6) | 43.7 (15.2) | .980 |
| Recipient age, yearsa | 52.2 (13.4) | 52.6 (12.1) | .825 |
| Donor sex, male | 301 (72) | 60 (76) | .445 |
| Recipient sex, male | 282 (67) | 48 (60) | .247 |
| Cold ischemia time, hoursb | 18.1 (16.2–21.1) | 18.0 (15.5–20.7) | .417 |
| Time on dialysis, monthsb | 16.7 (5.8–30.9) | 17.2 (7.0–27.0) | .672 |
| Thymoglobulin treatment | 159 (38) | 38 (48) | .116 |
| imTOR treatment | 13 (3) | 6 (8) | .016 |
| CMV serostatus (D+/R−) | 64 (15) | 8 (10) | .273 |
| CMV prophylaxis | 230 (55) | 47 (59) | .527 |
| Sensitized patients | 28 (7) | 3 (4) | .403 |
| HLA mismatcha | 4.2 (1.1) | 4.3 (1.2) | .237 |
| Delayed graft function | 201 (48) | 33 (42) | .413 |
| Acute rejection | 71 (17) | 16 (21) | .511 |
| CMV infection | 167 (40) | 18 (23) | .013 |
| CMV disease | 33 (8) | 0 (0) | .009 |
| Loss graft | 29 (7) | 9 (12) | .096 |
| Exitus | 25 (6) | 4 (5) | .817 |
| Follow-up, monthsb | 59.1 (34.9–89.0) | 55.1 (32.8–88.1) | .743 |
Abbreviations: CMV, cytomegalovirus; HLA, human leukocyte antigen; IL, interleukin; imTOR, inhibitors of mammalian target of rapamycin; IQR, interquartile range.
aData expressed as mean (standard deviation).
bData expressed as median (IQR).